Insulin degludec/insulin aspart produces a dose‐proportional glucose‐lowering effect in subjects with type 1 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 659-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naïve subjects with type 2 diabetes

By Yang Wenying   Xu Xiangjin   Liu Xiaomin   Yang Gangyi   Seino Yutaka   Andersen Henning   Jinnouchi Hideaki  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1599-1608

Informa Healthcare

Access to resources Recommend Favorite

Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin

By McAdam-Marx Carrie   Yu Junhua   Bouchard Jonathan   Aagren Mark   Brixner Diana I.  

Current Medical Research and Opinion, Vol. 26, Iss. 1, 2010-01 ,pp. : 191-201

Informa Healthcare

Access to resources Recommend Favorite

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 3, 2015-05 ,pp. : 164-176

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

By Bergenstal Richard   Lewin Andrew   Bailey Timothy   Chang Denise   Gylvin Titus   Roberts Victor    

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 65-75

Informa Healthcare

Access to resources Recommend Favorite